Journal home > Archive > Clinical > Abstract Clinical British Journal of Cancer (2004) 91, 618–620. doi:10.1038/sj.bjc.6601971 www.bjcancer.com Published online 3 August 2004 Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study C Ficorella1, M F Morelli1, E Ricevuto1, K Cannita1, G Porzio1, P Lanfiuti Baldi1, G Cianci1, ZC Di Rocco1, C Natoli2, N Tinari2, F De Galitiis1, F Calista1 and P Marchetti1 1Medical Oncology, University of L'Aquila, Italy 2Department of Oncology and Neuroscience Section of Medical Oncology, University of Chieti, Italy Correspondence: Dr C Ficorella, Department of Experimental Medicine, University of L'Aquila, Via Vetoio, Coppito, L'Aquila 67100, Italy. E-mail: ficorella@interfree.it Received 4 February 2004; Revised 7 May 2004; Accepted 10 May 2004; Published online 3 August 2004. Top of pageAbstract A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00–10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients. This schedule seems to reduce the occurrence of stomatitis of the docetaxel and infusional 5-FU regimen. Keywords: breast cancer, docetaxel, 5-fluorouracil Top of page MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REVIEWS Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases Nature Clinical Practice Gastroenterology & Hepatology Review (01 Sep 2005)
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study
FICORELLA, Corrado;RICEVUTO, Enrico;
2004-01-01
Abstract
Journal home > Archive > Clinical > Abstract Clinical British Journal of Cancer (2004) 91, 618–620. doi:10.1038/sj.bjc.6601971 www.bjcancer.com Published online 3 August 2004 Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study C Ficorella1, M F Morelli1, E Ricevuto1, K Cannita1, G Porzio1, P Lanfiuti Baldi1, G Cianci1, ZC Di Rocco1, C Natoli2, N Tinari2, F De Galitiis1, F Calista1 and P Marchetti1 1Medical Oncology, University of L'Aquila, Italy 2Department of Oncology and Neuroscience Section of Medical Oncology, University of Chieti, Italy Correspondence: Dr C Ficorella, Department of Experimental Medicine, University of L'Aquila, Via Vetoio, Coppito, L'Aquila 67100, Italy. E-mail: ficorella@interfree.it Received 4 February 2004; Revised 7 May 2004; Accepted 10 May 2004; Published online 3 August 2004. Top of pageAbstract A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00–10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients. This schedule seems to reduce the occurrence of stomatitis of the docetaxel and infusional 5-FU regimen. Keywords: breast cancer, docetaxel, 5-fluorouracil Top of page MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REVIEWS Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases Nature Clinical Practice Gastroenterology & Hepatology Review (01 Sep 2005)Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
